Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on November 9, 2020. The registrant is a Delaware corporation headquartered in Alameda, California, and is classified as an emerging growth company. The filing discloses a new debt obligation and the issuance of unregistered equity securities.
Key Financial Metrics and Obligations
The filing details a specific financing transaction rather than comprehensive period-end financial statements.
- New Debt: Borrowed an additional $1.0 million under a Secured Convertible Facility Agreement with Juvenescence Limited.
- Repayment Date: The outstanding principal balance is due on March 30, 2023.
- Equity Issuance: Issued warrants to purchase 280,898 shares of common stock.
- Warrant Exercise Price: $1.78 per share.
- Revenue, Profit, and Cash Flow: The filing text does not provide a clear value for revenue, net income, operating cash flow, or liquidity ratios for the reporting period.
Material Changes and Transaction Details
The primary material change is the drawdown of $1.0 million in credit on November 9, 2020, under an existing facility originally dated March 30, 2020, and amended on July 21, 2020. In connection with this draw, the company issued unregistered warrants to the lender, Juvenescence Limited, relying on exemptions under Section 4(a)(2) of the Securities Act and Regulation S.
Outlook, Risks, and Contingencies
The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to various risk factors.
Events of Default: The New Loan Agreement contains extensive default provisions that could accelerate repayment prior to the March 30, 2023 maturity date. Key triggers include:
- Failure to pay amounts due or perform obligations within 10 business days of notice.
- Default on other indebtedness exceeding $100,000 or failure to pay indebtedness exceeding $25,000 when due.
- Insolvency, liquidation, or inability to pay debts as they become due.
- Material adverse changes in financial condition or business operations.
- Loss or destruction of material collateral.
- Material asset dispositions without lender approval.
Investor Verification Checklist
- Verify the total outstanding principal balance under the Secured Convertible Facility Agreement following this $1.0 million draw.
- Confirm the listing status of the 280,898 warrants on the NYSE American.
- Review the company's current liquidity position to assess the ability to meet the March 30, 2023 repayment obligation.
- Examine the "Risk Factors" section in the most recent 10-K or 10-Q for details on the company's financial condition and operational risks.
- Check for any subsequent filings regarding the validity or perfection of security interests pledged to Juvenescence.